Protons substantially reduce kidney and bowel dose in prostate nodal reirradiation planning

In 15 prostate nodal recurrence cases, IMPT maintained target coverage while substantially reducing kidney, bowel and integral dose compared with VMAT.

KEY POINTS

  • This retrospective planning study from Johns Hopkins University evaluated 15 patients with pelvic and/or para-aortic nodal recurrence of prostate cancer after previous radiotherapy. All had received earlier treatment to the prostate or prostate fossa, with or without pelvic nodal irradiation. New VMAT and intensity-modulated proton therapy (IMPT) plans were generated using standardized target and OAR contours, while 11 patients had sufficiently complete previous treatment records for cumulative dose comparison.
  • Reirradiation prescriptions were standardized to 50.4 Gy in 28 fractions for elective pelvic and para-aortic nodal chains, with a simultaneous integrated boost to 63 Gy in 28 fractions for gross nodal disease. VMAT plans used two or three coplanar arcs, while IMPT employed three or four posterior or posterolateral beams. Proton plans incorporated ±3.5% range and 5-mm setup uncertainty in robust optimization, using a fixed RBE of 1.1.
  • Target coverage was comparable between modalities. For the elective nodal CTV, the volume receiving at least 49.90 Gy was 99.97% with IMPT versus 100% with VMAT (p=0.108). For the gross nodal CTV, corresponding coverage at 62.37 Gy was 99.66% versus 99.95% (p=0.080). No statistically significant differences were demonstrated across the principal CTV and PTV coverage endpoints, indicating that OAR sparing was achieved without a meaningful nominal target-coverage penalty.
  • IMPT substantially reduced bowel irradiation, especially at low and intermediate doses. In the nominal reirradiation plans, bowel cavity V15Gy decreased from 2,112.8 to 274.8 cm³ (p<0.001), V45Gy from 172.4 to 116.8 cm³ (p<0.001), and V55Gy from 37.4 to 16.1 cm³ (p<0.001). The low-dose bowel reduction was particularly pronounced, reflecting the difference between broad photon exposure and more localized proton beam deposition.
  • Kidney sparing was another major advantage of IMPT. Mean left kidney dose decreased from 9.07 to 1.68 Gy, and mean right kidney dose from 9.54 to 1.82 Gy (both p<0.001). Kidney V18Gy decreased from 13.83% to 2.69% on the left and 17.55% to 3.20% on the right. In addition, rectal D0.5cc decreased from 11.11 to 2.95 Gy (p=0.008), while total integral dose to body minus CTV decreased from 237.7 to 110.1 J (p<0.001).
  • The dosimetric advantages largely persisted when previous irradiation was incorporated. Among 11 evaluable composite plans, bowel cavity V45Gy was 173.4 cm³ with IMPT versus 238.9 cm³ with VMAT (p<0.001). Composite mean left kidney dose was 1.70 versus 9.61 Gy, and right kidney dose 2.13 versus 9.71 Gy (both p<0.001). Composite integral dose to body minus CTV was 105.7 versus 211.7 J (p<0.001). Differences in sigmoid dose were generally no longer statistically significant after cumulative dose assessment.
  • The analysis was exclusively dosimetric and cannot demonstrate safer clinical reirradiation. Previous treatment doses were mapped using image registration and combined with hypothetical standardized reirradiation plans, but no prospectively delivered matched photon-versus-proton treatments were compared. The sample size was small, only 11/15 patients contributed to composite analyses, and the study did not assess late GU/GI toxicity, bowel complications, patient-reported outcomes, or oncological control. Uncertainty from deformable dose mapping and changes in anatomy between radiation courses further limits the precision of cumulative estimates.

CLINICAL TAKEAWAY

IMPT may provide substantial dosimetric advantages over VMAT for pelvic and para-aortic nodal reirradiation in prostate cancer, particularly by reducing bowel, renal and whole-body integral dose while maintaining target coverage. These findings support individualized proton planning comparisons in previously irradiated patients, but prospective clinical data are needed to establish whether the observed dose reductions translate into meaningful toxicity benefits.

SOURCE

Cancers

Browse more research Suggest a correction